- Home
- SGMT vs MUE Comparison
SGMT vs MUE Comparison
Compare SGMT & MUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- MUE
- Stock Information
- Founded
- SGMT 2006
- MUE 1999
- Country
- SGMT United States
- MUE United States
- Employees
- SGMT N/A
- MUE N/A
- Industry
- SGMT
- MUE Investment Bankers/Brokers/Service
- Sector
- SGMT
- MUE Finance
- Exchange
- SGMT Nasdaq
- MUE Nasdaq
- Market Cap
- SGMT 238.7M
- MUE 219.4M
- IPO Year
- SGMT 2023
- MUE N/A
- Fundamental
- Price
- SGMT $7.31
- MUE $10.02
- Analyst Decision
- SGMT Strong Buy
- MUE
- Analyst Count
- SGMT 7
- MUE 0
- Target Price
- SGMT $26.57
- MUE N/A
- AVG Volume (30 Days)
- SGMT 480.3K
- MUE 62.6K
- Earning Date
- SGMT 11-12-2025
- MUE 01-01-0001
- Dividend Yield
- SGMT N/A
- MUE 4.09%
- EPS Growth
- SGMT N/A
- MUE N/A
- EPS
- SGMT N/A
- MUE N/A
- Revenue
- SGMT N/A
- MUE N/A
- Revenue This Year
- SGMT N/A
- MUE N/A
- Revenue Next Year
- SGMT N/A
- MUE N/A
- P/E Ratio
- SGMT N/A
- MUE N/A
- Revenue Growth
- SGMT N/A
- MUE N/A
- 52 Week Low
- SGMT $1.73
- MUE $8.53
- 52 Week High
- SGMT $11.41
- MUE $10.17
- Technical
- Relative Strength Index (RSI)
- SGMT 52.06
- MUE 64.24
- Support Level
- SGMT $7.11
- MUE $9.87
- Resistance Level
- SGMT $7.66
- MUE $10.13
- Average True Range (ATR)
- SGMT 0.40
- MUE 0.07
- MACD
- SGMT 0.11
- MUE -0.01
- Stochastic Oscillator
- SGMT 76.45
- MUE 57.69
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. The fund seeks to achieve its investment objective by investing in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes.